Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07499908Phase 1Not Yet Recruiting

Phase 1 Trial to Evaluate 150 mg Subcutaneous CIT-013

Role: lead

NCT06567470Phase 2Recruiting

A Study With CIT-013 in RA Patients

Role: lead

NCT06993233Phase 2Recruiting

A Study With CIT-013 in HS Patients

Role: lead

NCT07147959Phase 2Recruiting

PET-Based Imaging of Radiolabeled CIT-013

Role: lead

All 4 trials loaded